PL2914248T3 - Pharmaceutical compositions for the treatment of cftr mediated diseases - Google Patents

Pharmaceutical compositions for the treatment of cftr mediated diseases

Info

Publication number: PL2914248T3
Authority: PL; Poland
Prior art keywords: treatment; pharmaceutical compositions; mediated diseases; cftr mediated; cftr
Prior art date: 2012-11-02

Application number

PL13792149T

Other languages

Polish (pl)

Other versions

PL2914248T5 (en

Inventor

Marinus Jacobus Verwijs

Radhika KARKARE

Michael Douglas Moore

Original Assignee

Vertex Pharmaceuticals Incorporated

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-11-02

Filing date

2013-11-01

Publication date

2019-01-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50628072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2914248(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-11-01 Application filed by Vertex Pharmaceuticals Incorporated filed Critical Vertex Pharmaceuticals Incorporated

2019-01-31 Publication of PL2914248T3 publication Critical patent/PL2914248T3/en

2024-01-15 Publication of PL2914248T5 publication Critical patent/PL2914248T5/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Dispersion Chemistry (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Pulmonology (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

PL13792149.0T 2012-11-02 2013-11-01 Pharmaceutical compositions for the treatment of cftr mediated diseases PL2914248T5 (en)

Applications Claiming Priority (7)

Application Number	Priority Date	Filing Date	Title
US201261721622P	2012-11-02	2012-11-02
US201261728328P	2012-11-20	2012-11-20
US201361770668P	2013-02-28	2013-02-28
US201361824005P	2013-05-16	2013-05-16
US201361840668P	2013-06-28	2013-06-28
EP13792149.0A EP2914248B2 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases
PCT/US2013/067952 WO2014071122A1 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases

Publications (2)

Publication Number	Publication Date
PL2914248T3 true PL2914248T3 (en)	2019-01-31
PL2914248T5 PL2914248T5 (en)	2024-01-15

Family

ID=50628072

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL13792149.0T PL2914248T5 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases
PL18192504.1T PL3470063T3 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL18192504.1T PL3470063T3 (en)	2012-11-02	2013-11-01	Pharmaceutical compositions for the treatment of cftr mediated diseases

Country Status (30)

Country	Link
US (4)	US20140163068A1 (en)
EP (3)	EP2914248B2 (en)
JP (4)	JP6302923B2 (en)
KR (1)	KR102396897B1 (en)
CN (2)	CN104869982A (en)
AR (1)	AR093340A1 (en)
AU (4)	AU2013337730B2 (en)
BR (1)	BR112015009913B1 (en)
CA (1)	CA2890106C (en)
CL (1)	CL2015001148A1 (en)
CY (1)	CY1121070T1 (en)
DK (2)	DK2914248T4 (en)
ES (2)	ES3009747T3 (en)
FI (2)	FI3470063T3 (en)
HR (2)	HRP20181740T4 (en)
HU (2)	HUE070382T2 (en)
IL (2)	IL283276B2 (en)
LT (2)	LT3470063T (en)
MX (2)	MX368353B (en)
NZ (2)	NZ708474A (en)
PL (2)	PL2914248T5 (en)
PT (2)	PT3470063T (en)
RS (2)	RS57831B2 (en)
SG (3)	SG10201913581UA (en)
SI (2)	SI3470063T1 (en)
SM (2)	SMT202500078T1 (en)
TR (1)	TR201815218T4 (en)
TW (2)	TW201422253A (en)
UA (2)	UA123631C2 (en)
WO (1)	WO2014071122A1 (en)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7973169B2 (en)	2003-09-06	2011-07-05	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding Cassette transporters
US7977322B2 (en)	2004-08-20	2011-07-12	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
ES2628026T3 (en)	2004-06-24	2017-08-01	Vertex Pharmaceuticals Incorporated	Conveyor modulators of the ATP binding cassette
JP5143738B2 (en)	2005-08-11	2013-02-13	バーテックスファーマシューティカルズインコーポレイテッド	Modulator of cystic fibrosis membrane conductance regulator
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
WO2007079139A2 (en)	2005-12-28	2007-07-12	Vertex Pharmaceuticals, Inc.	Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US7645789B2 (en)	2006-04-07	2010-01-12	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US10022352B2 (en)	2006-04-07	2018-07-17	Vertex Pharmaceuticals Incorporated	Modulators of ATP-binding cassette transporters
JP5420395B2 (en)	2006-04-07	2014-02-19	バーテックスファーマシューティカルズインコーポレイテッド	Modulator of ATP-binding cassette transporter
USRE50453E1 (en)	2006-04-07	2025-06-10	Vertex Pharmaceuticals Incorporated	Indole derivatives as CFTR modulators
US8563573B2 (en)	2007-11-02	2013-10-22	Vertex Pharmaceuticals Incorporated	Azaindole derivatives as CFTR modulators
NZ581259A (en)	2007-05-09	2012-07-27	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
AU2008302598B2 (en)	2007-08-24	2014-07-17	Vertex Pharmaceuticals Incorporated	Isothiazolopyridinones useful for the treatment of (inter alia) Cystic Fibrosis
AU2008322616B2 (en)	2007-11-16	2013-07-18	Vertex Pharmaceuticals Incorporated	Isoquinoline modulators of ATP-Binding Cassette transporters
EP2639222B1 (en)	2007-12-07	2016-08-31	Vertex Pharmaceuticals Incorporated	Process for producing cycloalkylcarboxiamido-pyridine benzoic acids
US20100036130A1 (en)	2007-12-07	2010-02-11	Vertex Pharmaceuticals Incorporated	Processes for producing cycloalkylcarboxamido-pyridine benzoic acids
HUE049642T2 (en)	2007-12-07	2020-09-28	Vertex Pharma	Solid forms of 3- (6- (1- (2,2-Difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
NZ720282A (en)	2008-02-28	2017-12-22	Vertex Pharma	Heteroaryl derivatives as cftr modulators
US12458635B2 (en)	2008-08-13	2025-11-04	Vertex Pharmaceuticals Incorporated	Pharmaceutical composition and administrations thereof
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
EP3330255B1 (en)	2009-03-20	2020-12-09	Vertex Pharmaceuticals Incorporated	Process for making modulators of cystic fibrosis transmembrane conductance regulator
US8802868B2 (en)	2010-03-25	2014-08-12	Vertex Pharmaceuticals Incorporated	Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
JP2013523836A (en)	2010-04-07	2013-06-17	バーテックスファーマシューティカルズインコーポレイテッド	Solid form of 3- (6- (1- (2,2-difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
LT3150198T (en)	2010-04-07	2021-12-10	Vertex Pharmaceuticals Incorporated	PHARMACEUTICAL COMPOSITION AND INTRODUCTION OF 3- (6- (1,2-DIFLUORBENZO [D] [1,3] DIOXOL-5-IL) CYCLOPROPARBOXAMIDE) -3-METHYLPYRIDIN-2-IL) BENZOIC ACID
RU2745977C2 (en)	2010-04-22	2021-04-05	Вертекс Фармасьютикалз Инкорпорейтед	Method of producing cycloalkylcarboxamido-indole compounds
HUE047354T2 (en)	2011-05-18	2020-04-28	Vertex Pharmaceuticals Europe Ltd	Deuterated derivatives of ivacaftor
SI2776427T1 (en)	2011-11-08	2017-05-31	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
RS60569B1 (en)	2012-01-06	2020-08-31	Lundbeck La Jolla Research Center Inc	Carbamate compounds and methods of making and using same
MX2014010253A (en)	2012-02-27	2014-11-12	Vertex Pharma	Pharmaceutical composition and administration thereof.
EP2872122A1 (en)	2012-07-16	2015-05-20	Vertex Pharmaceuticals Incorporated	Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
JP6302923B2 (en) *	2012-11-02	2018-03-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Pharmaceutical compositions for the treatment of diseases mediated by CFTR
US9303918B2 (en) *	2013-03-15	2016-04-05	Monosol Rx, Llc	Process for drying a wet film with control of loss on drying
US20160074374A1 (en) *	2013-04-26	2016-03-17	Vertex Pharmaceuticals Incorporated	Correctors acting through msd1 of cftr protein
JP6963896B2 (en)	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Methods of Preparing Pharmaceutical Compositions for the Treatment of CFTR-mediated Diseases
CN110840847B (en)	2014-04-15	2022-07-29	沃泰克斯药物股份有限公司	Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
JP6896619B2 (en)	2014-10-06	2021-06-30	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Cystic fibrosis transmembrane conductance regulator modulator
ES2702288T3 (en)	2014-10-07	2019-02-28	Vertex Pharma	Co-crystals of transmembrane conductance regulator modulators of cystic fibrosis
BR112017010406B1 (en)	2014-11-18	2021-03-09	Vertex Pharmaceuticals Incorporated	process of carrying out high-throughput testing of high-performance liquid chromatography
CN107849021A (en)	2015-05-11	2018-03-27	阿比德治疗公司	Method of treating inflammatory or neuropathic pain
HK1258473A1 (en)	2015-09-25	2019-11-15	Vertex Pharmaceuticals (Europe) Limited	Deuterated cftr potentiators
WO2017151725A1 (en) *	2016-03-03	2017-09-08	Nivalis Therapeutics, Inc.	Formulations of an s-nitrosoglutathione reductase inhibitor
AU2017240685B2 (en)	2016-03-31	2021-08-12	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US10376501B2 (en)	2016-04-25	2019-08-13	Druggability Technologies Ip Holdco Limited	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600270A2 (en)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Complexes of ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600271A2 (en) *	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Pharmaceutical composition comprising complex formulations of ivacaftor and lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
US10206915B2 (en)	2016-04-25	2019-02-19	Druggability Technologies Ip Holdco Limited	Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
HUP1600269A2 (en)	2016-04-25	2017-10-30	Druggability Tech Ip Holdco Ltd	Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US10383865B2 (en)	2016-04-25	2019-08-20	Druggability Technologies Ip Holdco Limited	Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them
RS62670B1 (en)	2016-09-30	2021-12-31	Vertex Pharma	Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
TN2019000148A1 (en)	2016-11-16	2020-10-05	Abide Therapeutics Inc	Pharmaceutical formulations
EP3541807B1 (en)	2016-11-16	2021-09-29	H. Lundbeck A/S	A crystalline form of a magl inhibitor
JOP20190125B1 (en)	2016-12-09	2022-03-14	Vertex Pharma	A modifier for the cystic fibrosis transmembrane conductance regulator, pharmaceutical formulations, methods of treatment, and a process for manufacturing the modifier
CA3066084A1 (en)	2017-06-08	2018-12-13	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3069226A1 (en)	2017-07-17	2019-01-24	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
CA3071278A1 (en)	2017-08-02	2019-02-07	Vertex Pharmaceuticals Incorporated	Processes for preparing pyrrolidine compounds
IL273831B2 (en)	2017-10-19	2024-10-01	Vertex Pharma	Crystal forms and preparations of CFTR modulators
WO2019109021A1 (en)	2017-12-01	2019-06-06	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
CA3085006A1 (en)	2017-12-08	2019-06-13	Vertex Pharmaceuticals Incorporated	Processes for making modulators of cystic fibrosis transmembrane conductance regulator
TWI810243B (en)	2018-02-05	2023-08-01	美商維泰克斯製藥公司	Pharmaceutical compositions for treating cystic fibrosis
AR114254A1 (en)	2018-02-15	2020-08-12	Vertex Pharma	CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATORS, PHARMACEUTICAL COMPOSITIONS, TREATMENT METHODS AND PREPARATION PROCESS OF MODULATORS
US20210139514A1 (en)	2018-04-05	2021-05-13	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2019200246A1 (en)	2018-04-13	2019-10-17	Alexander Russell Abela	Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
ES2943126T3 (en)	2018-11-14	2023-06-09	Vertex Pharma	Methods for the treatment of cystic fibrosis
AR118555A1 (en)	2019-04-03	2021-10-20	Vertex Pharma	MODULATING AGENTS OF THE TRANSMEMBRANE CONDUCTANCE REGULATOR OF CYSTIC FIBROSIS
WO2020214921A1 (en)	2019-04-17	2020-10-22	Vertex Pharmaceuticals Incorporated	Solid forms of modulators of cftr
EP4013760A1 (en)	2019-08-14	2022-06-22	Vertex Pharmaceuticals Incorporated	Crystalline forms of cftr modulators
BR112022002604A2 (en)	2019-08-14	2022-05-03	Vertex Pharma	Cctr modulators production process
JP7684279B2 (en)	2019-08-14	2025-05-27	バーテックスファーマシューティカルズインコーポレイテッド	Cystic fibrosis transmembrane conductance regulator modulators
TWI867024B (en)	2019-08-14	2024-12-21	美商維泰克斯製藥公司	Modulators of cystic fibrosis transmembrane conductance regulator
US11904006B2 (en)	2019-12-11	2024-02-20	University Of Iowa Research Foundation	Poly(diaminosulfide) particle-based vaccine
JP2023523219A (en)	2020-04-21	2023-06-02	ハー・ルンドベック・アクチエゼルスカベット	Synthesis of monoacylglycerol lipase inhibitors
WO2022194399A1 (en)	2020-07-13	2022-09-22	Idorsia Pharmaceuticals Ltd	Macrocycles as cftr modulators
CR20230120A (en)	2020-08-07	2023-09-01	Vertex Pharma	Modulators of cystic fibrosis transmembrane conductance regulator
AU2021356651A1 (en)	2020-10-07	2023-05-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076618A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076629A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076622A2 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2022076627A1 (en)	2020-10-07	2022-04-14	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230374038A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230373939A1 (en)	2020-10-07	2023-11-23	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
US20230416275A1 (en)	2020-10-07	2023-12-28	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4225446A1 (en)	2020-10-07	2023-08-16	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
MX2023004074A (en)	2020-10-07	2023-07-05	Vertex Pharma	MODULATORS OF THE REGULATOR OF TRANSMEMBRANE CONDUCTANCE OF CYSTIC FIBROSIS.
US12324802B2 (en)	2020-11-18	2025-06-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
EP4259139A1 (en)	2020-12-10	2023-10-18	Vertex Pharmaceuticals Incorporated	Methods of treatment for cystic fibrosis
US20240100183A1 (en) *	2020-12-11	2024-03-28	University Of Iowa Research Foundation	Compositions comprising molecules for cystic fibrosis treatment
CA3211232A1 (en) *	2021-03-09	2022-09-15	Hemant Bhagwat NARKHEDE	Oral film of cftr modulator(s)
JP2025506382A (en)	2022-02-03	2025-03-11	バーテックスファーマシューティカルズインコーポレイテッド	How to Treat Cystic Fibrosis
EP4476230A1 (en)	2022-02-08	2024-12-18	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
JP2025511393A (en)	2022-04-06	2025-04-15	バーテックスファーマシューティカルズインコーポレイテッド	Cystic fibrosis transmembrane conductance regulator modulators
JP2025517322A (en)	2022-05-16	2025-06-05	バーテックスファーマシューティカルズインコーポレイテッド	How to Treat Cystic Fibrosis
KR20250084132A (en)	2022-09-15	2025-06-10	이도르시아 파마슈티컬스 리미티드	Macrocyclic CFTR modulators
EP4587444A1 (en)	2022-09-15	2025-07-23	Idorsia Pharmaceuticals Ltd	Crystalline form of (3s,7s,10r,13r)-13-benzyl-20-fluoro-7-isobutyl-n-(2-(3-methoxy-1,2,4-oxadiazol-5-yl)ethyl)-6,9-dimethyl-1,5,8,11-tetraoxo-10-(2,2,2-trifluoroethyl)-1,2,3,4,5,6,7,8,9,10,11,12,13,14-tetradecahydro-[1]oxa[4,7,10,14]tetraazacycloheptadecino[16,17-f]quinoline-3-carboxamide
US20250268979A1 (en)	2022-09-15	2025-08-28	Idorsia Pharmaceuticals Ltd	Combination of macrocyclic cftr modulators with cftr correctors and / or cftr potentiators
WO2025076235A1 (en)	2023-10-04	2025-04-10	Vertex Pharmaceuticals Incorporated	Modulators of cystic fibrosis transmembrane conductance regulator
WO2025186214A1 (en)	2024-03-05	2025-09-12	Idorsia Pharmaceuticals Ltd	Macrocyclic cftr modulators

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20020017295A1 (en)	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6777400B2 (en)	2000-08-05	2004-08-17	Smithkline Beecham Corporation	Anti-inflammatory androstane derivative compositions
BR0314943A (en)	2002-09-30	2005-08-02	Univ California	Cystic Fibrosis Transmembrane Conductance Regulatory Protein Inhibitors and Uses of These
US20050113423A1 (en)	2003-03-12	2005-05-26	Vangoor Frederick F.	Modulators of ATP-binding cassette transporters
HUE047569T2 (en)	2003-04-11	2020-04-28	Ptc Therapeutics Inc	1,2,4-oxadiazole benzoic acid compound and its use for nonsense suppression and the treatment of disease
WO2004110352A2 (en)	2003-05-16	2004-12-23	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-cftr and uses thereof
WO2004111014A1 (en)	2003-06-06	2004-12-23	Vertex Pharmaceuticals Incorporated	Pyrimidine derivatives as modulators of atp-binding cassette transporters
CA2465565A1 (en) *	2003-06-12	2004-12-12	Warner-Lambert Company Llc	Pharmaceutical compositions of atorvastatin
JP2007509044A (en)	2003-10-08	2007-04-12	バーテックス　ファーマシューティカルズ　インコーポレイテッド	Modulator of ATP binding cassette transporter containing cycloalkylpyranyl group
MXPA06005343A (en)	2003-11-14	2006-07-10	Vertex Pharma	Thiazoles and oxazoles useful as modulators of atp-binding cassette transporters.
CA2561560A1 (en)	2004-03-30	2005-10-13	The Regents Of The University Of California	Hydrazide-containing cftr inhibitor compounds and uses thereof
AU2005251745A1 (en)	2004-06-04	2005-12-22	The Regents Of The University Of California	Compounds having activity in increasing ion transport by mutant-CFTR and uses thereof
ES2628026T3 (en)	2004-06-24	2017-08-01	Vertex Pharmaceuticals Incorporated	Conveyor modulators of the ATP binding cassette
US9611230B2 (en)	2004-10-13	2017-04-04	Ptc Therapeutics, Inc.	1,3,4-oxadiazole benzoic acid compounds and their use for nonsense suppression and the treatment of disease
WO2006099256A2 (en)	2005-03-11	2006-09-21	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
RU2007138584A (en)	2005-03-18	2009-04-27	Дзе Риджентс Оф Дзе Юниверсити Оф Калифорния (Us)	ACTIVITY COMPOUNDS FOR CORRECTION OF MUTANT CFTR PROCESSING, AND THEIR APPLICATION
ES2683359T3 (en)	2005-04-08	2018-09-26	Ptc Therapeutics, Inc.	Compositions comprising a 1,2,4-oxadiazole and uses thereof to treat diseases associated with a premature stop codon
AU2006251624A1 (en)	2005-05-24	2006-11-30	Vertex Pharmaceuticals Incorporated	Modulators of ATP-Binding cassette transporters
CA2624683A1 (en)	2005-10-06	2007-04-19	Vertex Pharmaceuticals Incorporated	Modulators of atp-binding cassette transporters
EP1945632B1 (en)	2005-11-08	2013-09-18	Vertex Pharmaceuticals Incorporated	Heterocyclic modulators of atp-binding cassette transporters
ES2361595T3 (en)	2007-05-07	2011-06-20	Novartis Ag	ORGANIC COMPOUNDS.
JP2010540417A (en) *	2007-09-14	2010-12-24	バーテックスファーマシューティカルズインコーポレイテッド	Solid form of N- [2,4-bis (1,1-dimethylethyl) -5-hydroxyphenyl] -1,4-dihydro-4-oxoquinoline-3-carboxamide
HUE049642T2 (en)	2007-12-07	2020-09-28	Vertex Pharma	Solid forms of 3- (6- (1- (2,2-Difluorobenzo [d] [1,3] dioxol-5-yl) cyclopropanecarboxamido) -3-methylpyridin-2-yl) benzoic acid
WO2009074575A2 (en)	2007-12-10	2009-06-18	Novartis Ag	Organic compounds
CN102112130A (en)	2008-06-10	2011-06-29	诺瓦提斯公司	Pyrazine derivatives as epithelial sodium channel blockers
US20100074949A1 (en)	2008-08-13	2010-03-25	William Rowe	Pharmaceutical composition and administration thereof
SMT202100077T1 (en) *	2008-08-13	2021-05-07	Vertex Pharma	Pharmaceutical composition and administrations thereof
AR073709A1 (en)	2008-09-29	2010-11-24	Vertex Pharma	ACID DOSE UNITS 3- (6- (1- (2,2-DIFLUOROBENZENE (D) (1,3) DIOXOL-5-IL) CYCLOPROPANCARBOXAMIDE) -3-METHYLPIRIDIN-2-IL) BENZOIC
JP2012528875A (en) *	2009-06-02	2012-11-15	ナイカンファーマシューティカルズ，エルエルシー	Antagonism of human formyl peptide receptor for treatment of disease
JP2011034380A (en) *	2009-08-03	2011-02-17	Nitto Denko Corp	Touch panel and touch panel-equipped display device
WO2011028740A1 (en)	2009-09-03	2011-03-10	Glaxo Group Limited	ENaC BLOCKERS
WO2011079087A1 (en)	2009-12-23	2011-06-30	Glaxo Group Limited	Enac blockers
US8247436B2 (en)	2010-03-19	2012-08-21	Novartis Ag	Pyridine and pyrazine derivative for the treatment of CF
LT3150198T (en) *	2010-04-07	2021-12-10	Vertex Pharmaceuticals Incorporated	PHARMACEUTICAL COMPOSITION AND INTRODUCTION OF 3- (6- (1,2-DIFLUORBENZO [D] [1,3] DIOXOL-5-IL) CYCLOPROPARBOXAMIDE) -3-METHYLPYRIDIN-2-IL) BENZOIC ACID
EP3138563A1 (en) *	2010-04-22	2017-03-08	Vertex Pharmaceuticals Inc.	Pharmaceutical compositions and administrations thereof
US8372845B2 (en)	2010-09-17	2013-02-12	Novartis Ag	Pyrazine derivatives as enac blockers
US10105356B2 (en) *	2011-01-31	2018-10-23	Avalyn Pharma Inc.	Aerosol pirfenidone and pyridone analog compounds and uses thereof
US9968607B2 (en)	2011-04-25	2018-05-15	Hetero Research Foundation	Pharmaceutical compositions of raltegravir, methods of preparation and methods of use therof
NZ727015A (en) *	2012-01-25	2017-12-22	Vertex Pharma	Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
JP6302923B2 (en) *	2012-11-02	2018-03-28	バーテックスファーマシューティカルズインコーポレイテッドＶｅｒｔｅｘＰｈａｒｍａｃｅｕｔｉｃａｌｓＩｎｃｏｒｐｏｒａｔｅｄ	Pharmaceutical compositions for the treatment of diseases mediated by CFTR
JP6963896B2 (en) *	2013-11-12	2021-11-10	バーテックスファーマシューティカルズインコーポレイテッドVertex Pharmaceuticals Incorporated	Methods of Preparing Pharmaceutical Compositions for the Treatment of CFTR-mediated Diseases

2013
- 2013-11-01 JP JP2015540796A patent/JP6302923B2/en active Active
- 2013-11-01 NZ NZ708474A patent/NZ708474A/en unknown
- 2013-11-01 CN CN201380066317.9A patent/CN104869982A/en active Pending
- 2013-11-01 PL PL13792149.0T patent/PL2914248T5/en unknown
- 2013-11-01 CN CN202010527346.2A patent/CN111671751A/en active Pending
- 2013-11-01 HU HUE18192504A patent/HUE070382T2/en unknown
- 2013-11-01 HU HUE13792149A patent/HUE039864T2/en unknown
- 2013-11-01 MX MX2015005559A patent/MX368353B/en active IP Right Grant
- 2013-11-01 SG SG10201913581UA patent/SG10201913581UA/en unknown
- 2013-11-01 SI SI201332096T patent/SI3470063T1/en unknown
- 2013-11-01 ES ES18192504T patent/ES3009747T3/en active Active
- 2013-11-01 SM SM20250078T patent/SMT202500078T1/en unknown
- 2013-11-01 TW TW102139864A patent/TW201422253A/en unknown
- 2013-11-01 KR KR1020157014464A patent/KR102396897B1/en active Active
- 2013-11-01 RS RS20181318A patent/RS57831B2/en unknown
- 2013-11-01 CA CA2890106A patent/CA2890106C/en active Active
- 2013-11-01 SM SM20180590T patent/SMT201800590T1/en unknown
- 2013-11-01 PT PT181925041T patent/PT3470063T/en unknown
- 2013-11-01 LT LTEP18192504.1T patent/LT3470063T/en unknown
- 2013-11-01 DK DK13792149.0T patent/DK2914248T4/en active
- 2013-11-01 TR TR2018/15218T patent/TR201815218T4/en unknown
- 2013-11-01 NZ NZ745659A patent/NZ745659A/en unknown
- 2013-11-01 EP EP13792149.0A patent/EP2914248B2/en active Active
- 2013-11-01 WO PCT/US2013/067952 patent/WO2014071122A1/en not_active Ceased
- 2013-11-01 FI FIEP18192504.1T patent/FI3470063T3/en active
- 2013-11-01 BR BR112015009913-0A patent/BR112015009913B1/en active IP Right Grant
- 2013-11-01 LT LTEP13792149.0T patent/LT2914248T/en unknown
- 2013-11-01 UA UAA201803746A patent/UA123631C2/en unknown
- 2013-11-01 US US14/069,571 patent/US20140163068A1/en not_active Abandoned
- 2013-11-01 FI FIEP13792149.0T patent/FI2914248T4/en active
- 2013-11-01 TW TW107117580A patent/TWI736768B/en active
- 2013-11-01 UA UAA201505319A patent/UA117464C2/en unknown
- 2013-11-01 HR HRP20181740TT patent/HRP20181740T4/en unknown
- 2013-11-01 SG SG10201703452PA patent/SG10201703452PA/en unknown
- 2013-11-01 RS RS20250226A patent/RS66596B1/en unknown
- 2013-11-01 HR HRP20250100TT patent/HRP20250100T1/en unknown
- 2013-11-01 SG SG11201503365YA patent/SG11201503365YA/en unknown
- 2013-11-01 SI SI201331163T patent/SI2914248T2/en unknown
- 2013-11-01 ES ES13792149T patent/ES2694290T5/en active Active
- 2013-11-01 AU AU2013337730A patent/AU2013337730B2/en active Active
- 2013-11-01 PT PT13792149T patent/PT2914248T/en unknown
- 2013-11-01 PL PL18192504.1T patent/PL3470063T3/en unknown
- 2013-11-01 EP EP24223819.4A patent/EP4556008A3/en active Pending
- 2013-11-01 DK DK18192504.1T patent/DK3470063T3/en active
- 2013-11-01 EP EP18192504.1A patent/EP3470063B1/en active Active
- 2013-11-01 IL IL283276A patent/IL283276B2/en unknown
- 2013-11-04 AR ARP130104018A patent/AR093340A1/en not_active Application Discontinuation
2015
- 2015-04-30 CL CL2015001148A patent/CL2015001148A1/en unknown
- 2015-04-30 IL IL238551A patent/IL238551B/en active IP Right Grant
- 2015-04-30 MX MX2019011662A patent/MX2019011662A/en unknown
2016
- 2016-05-11 US US15/152,092 patent/US20160324846A1/en not_active Abandoned
2018
- 2018-03-05 JP JP2018038741A patent/JP2018090626A/en not_active Withdrawn
- 2018-09-14 AU AU2018229528A patent/AU2018229528A1/en not_active Abandoned
- 2018-11-30 CY CY20181101277T patent/CY1121070T1/en unknown
2019
- 2019-05-07 JP JP2019087813A patent/JP7003085B2/en active Active
- 2019-12-20 US US16/722,290 patent/US20200338063A1/en not_active Abandoned
2020
- 2020-06-17 AU AU2020204037A patent/AU2020204037B2/en active Active
2021
- 2021-12-28 JP JP2021214209A patent/JP2022034069A/en active Pending
2022
- 2022-12-30 US US18/091,472 patent/US20230364073A1/en active Pending
2024
- 2024-01-16 AU AU2024200273A patent/AU2024200273A1/en active Pending

Also Published As

Publication number	Publication date
JP2015535289A (en)	2015-12-10
MX2019011662A (en)	2019-11-18
IL238551B (en)	2021-06-30
CN111671751A (en)	2020-09-18
TR201815218T4 (en)	2018-11-21
IL283276B1 (en)	2024-01-01
CN104869982A (en)	2015-08-26
DK3470063T3 (en)	2025-01-20
JP2022034069A (en)	2022-03-02
TW201842907A (en)	2018-12-16
ES3009747T3 (en)	2025-03-31
RU2015120798A (en)	2016-12-27
SG11201503365YA (en)	2015-06-29
US20140163068A1 (en)	2014-06-12
RS57831B2 (en)	2024-02-29
WO2014071122A1 (en)	2014-05-08
BR112015009913A2 (en)	2017-07-11
UA123631C2 (en)	2021-05-05
RS66596B1 (en)	2025-04-30
UA117464C2 (en)	2018-08-10
LT2914248T (en)	2018-11-26
PT2914248T (en)	2018-11-29
MX368353B (en)	2019-09-30
SG10201913581UA (en)	2020-02-27
PL3470063T3 (en)	2025-04-14
FI3470063T3 (en)	2025-03-05
HRP20250100T1 (en)	2025-03-28
AU2020204037B2 (en)	2023-10-19
DK2914248T3 (en)	2018-11-26
ES2694290T3 (en)	2018-12-19
AU2013337730B2 (en)	2018-06-14
CA2890106A1 (en)	2014-05-08
HRP20181740T1 (en)	2018-12-28
KR102396897B1 (en)	2022-05-13
FI2914248T4 (en)	2023-12-19
KR20150080609A (en)	2015-07-09
CY1121070T1 (en)	2020-05-29
JP6302923B2 (en)	2018-03-28
IL238551A0 (en)	2015-06-30
JP2019142956A (en)	2019-08-29
SI2914248T1 (en)	2018-12-31
BR112015009913A8 (en)	2019-09-17
CL2015001148A1 (en)	2016-02-19
JP7003085B2 (en)	2022-02-04
DK2914248T4 (en)	2024-01-02
AR093340A1 (en)	2015-06-03
EP3470063A1 (en)	2019-04-17
EP2914248A1 (en)	2015-09-09
NZ745659A (en)	2020-04-24
HRP20181740T4 (en)	2024-01-05
RU2019117882A (en)	2019-10-04
TW201422253A (en)	2014-06-16
IL283276B2 (en)	2024-05-01
ES2694290T5 (en)	2024-05-21
AU2018229528A1 (en)	2018-10-11
SI2914248T2 (en)	2023-12-29
EP3470063B1 (en)	2025-01-01
AU2024200273A1 (en)	2024-02-01
PL2914248T5 (en)	2024-01-15
IL283276A (en)	2021-07-29
LT3470063T (en)	2025-02-10
US20160324846A1 (en)	2016-11-10
SG10201703452PA (en)	2017-06-29
EP2914248B2 (en)	2023-10-18
HK1212632A1 (en)	2016-06-17
MX2015005559A (en)	2015-10-29
EP2914248B1 (en)	2018-09-05
US20200338063A1 (en)	2020-10-29
PT3470063T (en)	2025-03-10
NZ708474A (en)	2019-02-22
EP4556008A3 (en)	2025-08-27
US20230364073A1 (en)	2023-11-16
EP4556008A2 (en)	2025-05-21
BR112015009913B1 (en)	2023-04-11
HUE039864T2 (en)	2019-02-28
JP2018090626A (en)	2018-06-14
TWI736768B (en)	2021-08-21
AU2020204037A1 (en)	2020-07-09
RU2692676C2 (en)	2019-06-26
SMT201800590T1 (en)	2019-01-11
CA2890106C (en)	2022-08-02
AU2013337730A1 (en)	2015-06-11
SMT202500078T1 (en)	2025-03-12
SI3470063T1 (en)	2025-04-30
HUE070382T2 (en)	2025-06-28
RS57831B1 (en)	2018-12-31

Publication	Publication Date	Title
IL277470A (en)	2020-11-30	Process of preparing pharmaceutical compositions for the treatment of cftr mediated diseases
SG10201703452PA (en)	2017-06-29	Pharmaceutical compositions for the treatment of cftr mediated diseases
IL236221A (en)	2017-12-31	Thienopyridone derivatives and pharmaceutical compositions comprising them for the treatment of diseases
PT2818482T (en)	2019-08-06	Pharmaceutical composition for treatment of cancer
HUE045461T2 (en)	2019-12-30	Pharmaceutical composition for treatment of cancer
LT2925757T (en)	2017-12-27	Compounds and compositions for the treatment of parasitic diseases
IL234831B (en)	2020-10-29	Pharmaceutical compositions for combination therapy
IL235058A0 (en)	2014-12-31	Pharmaceutical combinations for the treatment of metabolic disorders
PL2814462T3 (en)	2018-02-28	Oil-based pharmaceutical composition for the treatment of gastrointestinal diseases
HUE039044T2 (en)	2018-12-28	Pharmaceutical composition for the treatment of multiple sclerosis
HUP1100245A2 (en)	2012-11-28	Pharmaceutical composition for the treatment of wounds
HUE043019T2 (en)	2019-07-29	Pharmaceutical compositions for combination therapy